Study Of Airway Bypass Treatment For Emphysema Begins

Main Category: Medical Devices / Diagnostics
Also Included In: Respiratory / Asthma;  Transplants / Organ Donations
Article Date: 18 Dec 2007 - 3:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Researchers at Sarasota Memorial Health Care System have announced the start of the EASE (Exhale Airway Stents for Emphysema) Trial, an international, multi-center clinical trial to explore an investigational treatment that may offer a significant new, minimally-invasive option for those suffering with advanced widespread emphysema. The study focuses on a procedure called airway bypass that involves creating pathways in the lung for trapped air to escape and in turn, relieve emphysema symptoms including shortness of breath.

Emphysema is a chronic, progressive, and irreversible lung disease characterized by the destruction of lung tissue. The loss of the lungs' natural elasticity and the collapse of airways in the lung combine to make exhalation ineffective, leaving the emphysema sufferer with hyperinflation because they can't get air out of their lungs. With hyperinflation, breathing becomes inefficient and the patient is always short of breath. Even the most nominal physical activities become difficult for emphysema patients and many become dependent on oxygen therapy.

"We are excited to be part of this study because currently treatment options for the emphysema patients are very limited and many patients have a very poor quality of life," states Kirk Voelker, MD, principal investigator of the study at Sarasota Memorial Hospital. "By creating new pathways for airflow with the airway bypass procedure, we hope to reduce hyperinflation and improve lung function. If patients can breathe easier it is likely to improve their quality of life."

During airway bypass, physicians will use a flexible bronchoscope to go through the mouth into the airways. There the physician will create new small pathways and place an Exhale® Drug-Eluting Stent - manufactured by Broncus Technologies, Inc. - to allow the trapped air in the lung to escape. Patients could see an immediate improvement in dyspnea (shortness of breath).

"The airway bypass procedure could be an excellent option for those who may be considering lung transplant or who may not be suitable candidates for lung transplant surgery, which is one of the only other treatment options available for patients with this type of emphysema," states Todd Horiuchi, MD and sub-investigator of the study at Sarasota Memorial Hospital.

Physicians commonly use bronchoscopes to examine the airways within the lungs. During the airway bypass procedure physicians will first use a Doppler probe inserted through the bronchoscope to identify a site in the airway that is away from blood vessels. A special needle is then used to make a small opening and an Exhale® Drug-Eluting Stent is placed in the passageway to keep it open. The procedure involves placing up to six drug-eluting stents. The total time of the procedure is approximately one to two hours.

This procedure is still under clinical investigation, but early data suggest it may hold promise for patients with emphysema.

Emphysema affects an estimated 60 million people worldwide with more than 3 million sufferers in the United States. There is no cure for emphysema.

----------------------------
Article adapted by Medical News Today from original press release.
----------------------------

About Sarasota Memorial:

Sarasota Memorial Hospital is an 806-bed regional medical center. For the third consecutive year, U.S. News & World Report magazine listed the organization in its prestigious "America's Best Hospitals" issue, ranking SMHCS among the top hospitals in the nation in six specialties (heart and heart surgery, cancer care, digestive disorders, orthopedics, respiratory disorders and gynecology) for 2006.

About Broncus Technologies

Broncus Technologies is helping people breathe easier by developing bronchoscopic interventions for the treatment of chronic lung diseases. Founded in 1997, Broncus Technologies has developed the Exhale® Drug-Eluting Stent for use in the airway bypass procedure, a minimally-invasive procedure to treat emphysema. Airway bypass creates new pathways in the lung for air to escape and may potentially improve the breathing abilities of patients with emphysema. Broncus Technologies is currently conducting the pivotal study EASE Trial to evaluate the safety and efficacy of airway bypass in the treatment of advanced widespread emphysema. For more information visit www.broncus.com.

For questions about enrolling in the trial visit www.EASEtrialUS.com.

Dr. Voelker has no personal direct financial affiliation with Broncus Technologies Inc. The study is sponsored by Broncus Technologies, Inc.

Broncus and Exhale are trademarks of Broncus Technologies, Inc.

Source: Meghan Oreste
Broncus Technologies